Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Gilead has not yet named a price for remdesivir yet. Photo: Liu Guanguan/China News Service via Getty Images

A fair price for Gilead's coronavirus drug, remdesivir, likely should not exceed $2,800 for a course of treatment, according to updated estimates from experts at the Institute for Clinical and Economic Review.

The bottom line: Gilead hasn't released a final price for remdesivir yet, and it could set the bar for other coronavirus treatments that come after it.

Details: ICER — which conducts cost-effectiveness analyses on drugs and other medical treatments — originally released remdesivir price estimates in May, but revised its figures as more information has come out:

  • $10 per treatment: Same low-end estimate assumes recovery of basic costs plus a small margin.
  • $310 per treatment: This price reflects the drug's current clinical benefit, which reduces hospitalization time but does not reduce the chance of death. (If the drug shows a mortality benefit later, this could go up to $5,000.)
  • $600 per treatment: Roughly what generic drug companies are charging for remdesivir overseas.
  • $1,600 per treatment: If Gilead tried to recoup new research costs.
  • $2,800 per treatment: This assumes dexamethasone becomes the new standard for hospitalized coronavirus patients, and "therefore the overall lives and life years saved with remdesivir are lower," ICER said.

Go deeper

Mark Meadows: Trump's blood oxygen level "dropped rapidly," but he's doing well

White House Chief of Staff Mark Meadows speaks to reporters about President Trump's positive coronavirus test outside the West Wing of the White House on Friday. Photo: Drew Angerer/Getty Images

White House Chief of Staff Mark Meadows told Fox News Saturday night that officials were "concerned" about President Trump's condition after he was diagnosed with the coronavirus, but he's now "doing well."

Why it matters: There have been conflicting reports from the White House on Trump's condition. Meadows' remarks come after White House physician Sean Conley said Saturday that Trump "remains fever-free and off supplemental oxygen," but that the president is "not yet out of the woods."

Updated Nov 9, 2020 - Health

23 states set single-day coronavirus case records last week

Data: Compiled by Axios; Map: Danielle Alberti/Axios

23 states set new highs last week for coronavirus infections recorded in a single day, according to the COVID Tracking Project (CTP) and state health departments. 15 states surpassed records from the previous week.

Why it matters: More states across the country are handling record-high caseloads than this summer.

Updated Oct 25, 2020 - Politics & Policy

Trumpworld coronavirus tracker

Photo: Saul Loeb/AFP via Getty Images

An outbreak of COVID-19 has struck the White House — including the president himself — just weeks before the 2020 election.

Why it matters: If the president can get infected, anyone can. And the scramble to figure out the scope of this outbreak is a high-profile, high-stakes microcosm of America's larger failures to contain the virus and to stand up a contact-tracing system that can respond to new cases before they have a chance to become outbreaks.